167 related articles for article (PubMed ID: 11180028)
1. Clinical trial simulation of docetaxel in patients with cancer as a tool for dosage optimization.
Veyrat-Follet C; Bruno R; Olivares R; Rhodes GR; Chaikin P
Clin Pharmacol Ther; 2000 Dec; 68(6):677-87. PubMed ID: 11180028
[TBL] [Abstract][Full Text] [Related]
2. Docetaxel in the treatment of non-small cell lung cancer: review of single-agent trials.
Fossella FV
Semin Oncol; 1999 Oct; 26(5 Suppl 16):17-23; discussion 41-2. PubMed ID: 10585004
[TBL] [Abstract][Full Text] [Related]
3. Alpha-1-acid glycoprotein as an independent predictor for treatment effects and a prognostic factor of survival in patients with non-small cell lung cancer treated with docetaxel.
Bruno R; Olivares R; Berille J; Chaikin P; Vivier N; Hammershaimb L; Rhodes GR; Rigas JR
Clin Cancer Res; 2003 Mar; 9(3):1077-82. PubMed ID: 12631610
[TBL] [Abstract][Full Text] [Related]
4. Docetaxel for previously treated non-small-cell lung cancer.
Fossella FV
Oncology (Williston Park); 2002 Jun; 16(6 Suppl 6):45-51. PubMed ID: 12108897
[TBL] [Abstract][Full Text] [Related]
5. Overview of docetaxel (Taxotere) in the treatment of non-small cell lung cancer.
Fossella FV
Semin Oncol; 1999 Jun; 26(3 Suppl 11):4-8. PubMed ID: 10458203
[TBL] [Abstract][Full Text] [Related]
6. The current status of docetaxel for advanced non-small cell lung cancer.
Green MR
Anticancer Drugs; 2001 Feb; 12 Suppl 1():S11-6. PubMed ID: 11340898
[TBL] [Abstract][Full Text] [Related]
7. Elderly patients benefit from second-line cytotoxic chemotherapy: a subset analysis of a randomized phase III trial of pemetrexed compared with docetaxel in patients with previously treated advanced non-small-cell lung cancer.
Weiss GJ; Langer C; Rosell R; Hanna N; Shepherd F; Einhorn LH; Nguyen B; Paul S; McAndrews P; Bunn PA; Kelly K
J Clin Oncol; 2006 Sep; 24(27):4405-11. PubMed ID: 16983108
[TBL] [Abstract][Full Text] [Related]
8. Docetaxel (Taxotere) in the treatment of non-small cell lung cancer (NSCLC)--is there a role for a new chemotherapy programme?
Armand JP
Gan To Kagaku Ryoho; 2000 May; 27 Suppl 2():223-30. PubMed ID: 10895158
[TBL] [Abstract][Full Text] [Related]
9. The development of docetaxel (Taxotere) in non-small cell lung cancer--docetaxel in new combinations and new schedules: an overview of ongoing and future developments.
Donnellan PP; Crown JP
Semin Oncol; 1997 Aug; 24(4 Suppl 14):S14-18-S14-21. PubMed ID: 9335519
[TBL] [Abstract][Full Text] [Related]
10. Docetaxel (Taxotere) and vinorelbine in the treatment of non-small cell lung cancer.
Georgoulias V; Kourousis C; Androulakis N; Kakolyris S; Papadakis E; Bouros D; Apostolopoulou F; Georgopoulou T; Agelidou M; Souglakos J; Halkiadakis G; Hatzidaki D
Semin Oncol; 1997 Aug; 24(4 Suppl 14):S14-9-S14-14. PubMed ID: 9335517
[TBL] [Abstract][Full Text] [Related]
11. Summary of phase II data of docetaxel (Taxotere), an active agent in the first- and second-line treatment of advanced non-small cell lung cancer.
Fossella FV; Lee JS; Berille J; Hong WK
Semin Oncol; 1995 Apr; 22(2 Suppl 4):22-9. PubMed ID: 7740327
[TBL] [Abstract][Full Text] [Related]
12. The role of docetaxel (Taxotere) as a single agent or in combination before local treatment of non-small cell lung cancer.
Harper P
Semin Oncol; 1997 Aug; 24(4 Suppl 14):S14-30-S14-32. PubMed ID: 9335522
[TBL] [Abstract][Full Text] [Related]
13. Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer.
Bruno R; Hille D; Riva A; Vivier N; ten Bokkel Huinnink WW; van Oosterom AT; Kaye SB; Verweij J; Fossella FV; Valero V; Rigas JR; Seidman AD; Chevallier B; Fumoleau P; Burris HA; Ravdin PM; Sheiner LB
J Clin Oncol; 1998 Jan; 16(1):187-96. PubMed ID: 9440742
[TBL] [Abstract][Full Text] [Related]
14. Docetaxel in the management of advanced non-small cell lung cancer.
Miller VA
Semin Oncol; 1998 Jun; 25(3 Suppl 8):15-9. PubMed ID: 9704671
[TBL] [Abstract][Full Text] [Related]
15. Prognostic score for second-line chemotherapy of advanced non-small-cell lung cancer: external validation in a phase III trial comparing vinflunine with docetaxel.
Di Maio M; Krzakowski M; Fougeray R; Kowalski DM; Gridelli C
Lung Cancer; 2012 Jul; 77(1):116-20. PubMed ID: 22361218
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of docetaxel in previously untreated extensive-stage small cell lung cancer: a Southwest Oncology Group phase II trial.
Hesketh PJ; Crowley JJ; Burris HA; Williamson SK; Balcerzak SP; Peereboom D; Goodwin JW; Gross HM; Moore DF; Livingston RB; Gandara DR
Cancer J Sci Am; 1999; 5(4):237-41. PubMed ID: 10439170
[TBL] [Abstract][Full Text] [Related]
17. Emerging role of docetaxel (Taxotere) in advanced non-small cell lung cancer.
Gandara DR; Edelman MJ; Lau D
Semin Oncol; 1999 Jun; 26(3 Suppl 10):3-7. PubMed ID: 10437743
[TBL] [Abstract][Full Text] [Related]
18. Paclitaxel (1-hour) and carboplatin (area under the concentration-time curve 7.5) in advanced non-small cell lung cancer: a phase II study of the Fox Chase Cancer Center and its network.
Langer CJ; Millenson M; Rosvold E; Litwin S; McAleer CA; Bonjo CA; Ozols R
Semin Oncol; 1997 Aug; 24(4 Suppl 12):S12-81-S12-88. PubMed ID: 9331128
[TBL] [Abstract][Full Text] [Related]
19. Concurrent conventionally factionated radiotherapy and weekly docetaxel in the treatment of stage IIIb non-small-cell lung carcinoma.
Koukourakis MI; Bahlitzanakis N; Froudarakis M; Giatromanolaki A; Georgoulias V; Koumiotaki S; Christodoulou M; Kyrias G; Skarlatos J; Kostantelos J; Beroukas K
Br J Cancer; 1999 Aug; 80(11):1792-6. PubMed ID: 10468298
[TBL] [Abstract][Full Text] [Related]
20. Consolidation docetaxel after concurrent chemoradiotherapy in stage IIIB non-small-cell lung cancer: phase II Southwest Oncology Group Study S9504.
Gandara DR; Chansky K; Albain KS; Leigh BR; Gaspar LE; Lara PN; Burris H; Gumerlock P; Kuebler JP; Bearden JD; Crowley J; Livingston R;
J Clin Oncol; 2003 May; 21(10):2004-10. PubMed ID: 12743155
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
